| Literature DB >> 16510036 |
Marzia Montalbano1, Guy W Neff.
Abstract
Liver transplant teams are often faced with the challenges of managing viral recurrence after liver transplantation. Hepatitis C virus (HCV) remains the most challenging viral disease in the transplant community. Strategies to prevent and delay viral recurrence have slowly developed over the past 5 years. Hepatitis B virus (HBV), previously a contraindication for liver transplantation due to recurrence and cholestasis with allograft failure, is now one of the more favorable indications for liver transplantation as a result of current therapeutic options. This review investigates the up-to-date information on treatment outcomes for HCV and HBV in the period following liver transplant.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16510036 DOI: 10.1007/s11894-006-0065-x
Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN: 1522-8037